Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Stock Regains 7 Percent of Value Lost After Positive Biomarker Discovery News

NEW YORK, May 26 (GenomeWeb News) - Shares in Ciphergen this afternoon regained the roughly 7 percent they lost yesterday despite news that the company discovered biomarkers that may predict the recurrence of prostate cancer.

Ciphergen's stock was trading up at $1.82 in mid-afternoon trading today -- right around where they opened on Wednesday morning -- after closing at $1.68 yesterday.

Ciphergen said yesterday morning that it had discovered two proteins that, in combination with PSA levels, may be useful within five years in the prediction of prostate cancer recurrence following surgery.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.